Targeted therapy and blood-brain barrier.
Due to defined molecular lesions and signaling pathway disruptions, brain tumors represent good candidates for targeted therapy. However, in brain tumors the blood-brain barrier may prevent the transfer of progress in the molecular neurosciences to the development of effective therapeutic strategies. In this article, the most advanced forms of targeted therapy for the treatment of brain tumors and their clinical results are presented.
Korfel
Agnieszka
A
Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Charité Universitätsmedizin Berlin, Germany.
Thiel
Eckhard
E
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000378:metabolism; D000906:Antibodies / Q000008:administration & dosage / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001932:Brain Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008081:Liposomes; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D020533:Angiogenesis Inhibitors; D000906:Antibodies; D000970:Antineoplastic Agents; D008081:Liposomes; D016376:Oligonucleotides, Antisense; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors